|
AU2013355054B2
(en)
|
2012-12-07 |
2017-08-24 |
Chemocentryx, Inc. |
Diazole lactams
|
|
TN2017000084A1
(en)
|
2014-09-11 |
2018-07-04 |
Bristol Myers Squibb Co |
Macrocyclic inhibitors of the pd-1/pd-l1 and cd80 (b7-1)/pd-li protein/protein interactions
|
|
US9732119B2
(en)
|
2014-10-10 |
2017-08-15 |
Bristol-Myers Squibb Company |
Immunomodulators
|
|
US9856292B2
(en)
|
2014-11-14 |
2018-01-02 |
Bristol-Myers Squibb Company |
Immunomodulators
|
|
US9861680B2
(en)
|
2014-12-18 |
2018-01-09 |
Bristol-Myers Squibb Company |
Immunomodulators
|
|
US9944678B2
(en)
|
2014-12-19 |
2018-04-17 |
Bristol-Myers Squibb Company |
Immunomodulators
|
|
US20160222060A1
(en)
|
2015-02-04 |
2016-08-04 |
Bristol-Myers Squibb Company |
Immunomodulators
|
|
US9809625B2
(en)
|
2015-03-18 |
2017-11-07 |
Bristol-Myers Squibb Company |
Immunomodulators
|
|
PT3297438T
(pt)
|
2015-05-21 |
2022-01-25 |
Chemocentryx Inc |
Moduladores de ccr2
|
|
US10143746B2
(en)
|
2016-03-04 |
2018-12-04 |
Bristol-Myers Squibb Company |
Immunomodulators
|
|
US10358463B2
(en)
*
|
2016-04-05 |
2019-07-23 |
Bristol-Myers Squibb Company |
Immunomodulators
|
|
IL261998B2
(en)
|
2016-04-07 |
2023-03-01 |
Chemocentryx Inc |
Reducing your burden by giving ccr1 antagonists in combination with pd-1 inhibitors or pd-l1 inhibitors
|
|
TWI794171B
(zh)
|
2016-05-11 |
2023-03-01 |
美商滬亞生物國際有限公司 |
Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
|
|
TWI808055B
(zh)
|
2016-05-11 |
2023-07-11 |
美商滬亞生物國際有限公司 |
Hdac 抑制劑與 pd-1 抑制劑之組合治療
|
|
BR112018073642A2
(pt)
|
2016-05-19 |
2019-02-26 |
Bristol-Myers Squibb Company |
imunomoduladores para imagiologia tep
|
|
FI3526323T3
(fi)
|
2016-10-14 |
2023-06-06 |
Prec Biosciences Inc |
Hepatiitti B -viruksen genomissa oleville tunnistussekvensseille spesifisiä muokattuja meganukleaaseja
|
|
EP3535280B1
(en)
|
2016-11-07 |
2022-03-16 |
Bristol-Myers Squibb Company |
Immunomodulators
|
|
EP3558395A4
(en)
|
2016-12-23 |
2020-08-12 |
The Johns Hopkins University |
IMAGING OF TUMOR CELLS AND IMMUNE CELLS BASED ON PD-L1 EXPRESSION
|
|
CN110121505B
(zh)
|
2016-12-28 |
2023-08-01 |
株式会社绿十字细胞治疗 |
嵌合抗原受体和表达其的自然杀伤细胞
|
|
KR102735038B1
(ko)
*
|
2017-06-23 |
2024-11-28 |
브리스톨-마이어스 스큅 컴퍼니 |
Pd-1의 길항제로서 작용하는 면역조정제
|
|
MA50665A
(fr)
|
2017-09-25 |
2020-08-05 |
Chemocentryx Inc |
Polythérapie utilisant un antagoniste du récepteur 2 de la chimiokine (ccr2) et un inhibiteur pd-1/pd-l1
|
|
EP3692053A1
(en)
|
2017-10-03 |
2020-08-12 |
Bristol-Myers Squibb Company |
Immunomodulators
|
|
EP3712178A4
(en)
|
2017-11-14 |
2021-08-11 |
Green Cross Lab Cell Corporation |
ANTI-HER2 ANTIBODIES OR ANTIGIBODY FRAGMENT THEREOF AND CHIMERAIR ANTIGEN RECEPTOR WITH IT
|
|
US11649294B2
(en)
|
2017-11-14 |
2023-05-16 |
GC Cell Corporation |
Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same
|
|
KR102492187B1
(ko)
|
2017-12-20 |
2023-01-27 |
인스티튜트 오브 오가닉 케미스트리 앤드 바이오케미스트리 에이에스 씨알 브이.브이.아이. |
Sting 어댑터 단백질을 활성화하는 포스포네이트 결합을 가진 3'3' 사이클릭 다이뉴클레오티드
|
|
JP7098748B2
(ja)
|
2017-12-20 |
2022-07-11 |
インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール，ヴイ．ヴイ．アイ． |
Ｓｔｉｎｇアダプタータンパク質を活性化するホスホン酸結合を有する２’３’環状ジヌクレオチド
|
|
IL275898B2
(en)
|
2018-01-08 |
2025-05-01 |
Chemocentryx Inc |
Methods for treating solid tumors with CCR2 antagonists
|
|
US20190269664A1
(en)
|
2018-01-08 |
2019-09-05 |
Chemocentryx, Inc. |
Methods of treating solid tumors with ccr2 antagonists
|
|
KR102526964B1
(ko)
|
2018-02-26 |
2023-04-28 |
길리애드 사이언시즈, 인코포레이티드 |
Hbv 복제 억제제로서의 치환된 피롤리진 화합물
|
|
US10870691B2
(en)
|
2018-04-05 |
2020-12-22 |
Gilead Sciences, Inc. |
Antibodies and fragments thereof that bind hepatitis B virus protein X
|
|
TW202005654A
(zh)
|
2018-04-06 |
2020-02-01 |
捷克科學院有機化學與生物化學研究所 |
２，２，─環二核苷酸
|
|
TWI818007B
(zh)
|
2018-04-06 |
2023-10-11 |
捷克科學院有機化學與生物化學研究所 |
2'3'-環二核苷酸
|
|
TWI833744B
(zh)
|
2018-04-06 |
2024-03-01 |
捷克科學院有機化學與生物化學研究所 |
3'3'-環二核苷酸
|
|
TW201945388A
(zh)
|
2018-04-12 |
2019-12-01 |
美商精密生物科學公司 |
對b型肝炎病毒基因體中之識別序列具有特異性之最佳化之經工程化巨核酸酶
|
|
US20190359645A1
(en)
|
2018-05-03 |
2019-11-28 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
2'3'-cyclic dinucleotides comprising carbocyclic nucleotide
|
|
JP7388635B2
(ja)
|
2018-05-31 |
2023-11-29 |
小野薬品工業株式会社 |
免疫チェックポイント阻害薬の有効性判定バイオマーカー
|
|
WO2019232319A1
(en)
|
2018-05-31 |
2019-12-05 |
Peloton Therapeutics, Inc. |
Compositions and methods for inhibiting cd73
|
|
WO2020028097A1
(en)
|
2018-08-01 |
2020-02-06 |
Gilead Sciences, Inc. |
Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid
|
|
TWI855000B
(zh)
|
2018-10-11 |
2024-09-11 |
日商小野藥品工業股份有限公司 |
Ｓｔｉｎｇ促效化合物
|
|
WO2020092528A1
(en)
|
2018-10-31 |
2020-05-07 |
Gilead Sciences, Inc. |
Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
|
|
PE20211655A1
(es)
|
2018-10-31 |
2021-08-24 |
Gilead Sciences Inc |
Compuestos de 6-azabencimidazol sustituidos como inhibidores de hpk1
|
|
CN113543851B
(zh)
|
2019-03-07 |
2025-03-18 |
捷克共和国有机化学与生物化学研究所 |
2’3’-环二核苷酸及其前药
|
|
WO2020178770A1
(en)
|
2019-03-07 |
2020-09-10 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
3'3'-cyclic dinucleotides and prodrugs thereof
|
|
WO2020178768A1
(en)
|
2019-03-07 |
2020-09-10 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
|
|
US20220195046A1
(en)
|
2019-03-28 |
2022-06-23 |
Bristol-Myers Squibb Company |
Methods of treating tumor
|
|
WO2020198672A1
(en)
|
2019-03-28 |
2020-10-01 |
Bristol-Myers Squibb Company |
Methods of treating tumor
|
|
TW202212339A
(zh)
|
2019-04-17 |
2022-04-01 |
美商基利科學股份有限公司 |
類鐸受體調節劑之固體形式
|
|
TW202210480A
(zh)
|
2019-04-17 |
2022-03-16 |
美商基利科學股份有限公司 |
類鐸受體調節劑之固體形式
|
|
WO2020237081A1
(en)
*
|
2019-05-21 |
2020-11-26 |
Bristol-Myers Squibb Company |
Immunomodulators
|
|
TWI826690B
(zh)
|
2019-05-23 |
2023-12-21 |
美商基利科學股份有限公司 |
經取代之烯吲哚酮化物及其用途
|
|
WO2020243568A1
(en)
|
2019-05-30 |
2020-12-03 |
Bristol-Myers Squibb Company |
Methods of identifying a subject suitable for an immuno-oncology (i-o) therapy
|
|
CN114174538A
(zh)
|
2019-05-30 |
2022-03-11 |
百时美施贵宝公司 |
适合于免疫肿瘤学疗法的多肿瘤基因特征
|
|
CN114174537A
(zh)
|
2019-05-30 |
2022-03-11 |
百时美施贵宝公司 |
细胞定位特征和组合疗法
|
|
CN114206386A
(zh)
|
2019-08-05 |
2022-03-18 |
小野药品工业株式会社 |
免疫检查点抑制剂的有效性判定生物标记
|
|
WO2021034804A1
(en)
|
2019-08-19 |
2021-02-25 |
Gilead Sciences, Inc. |
Pharmaceutical formulations of tenofovir alafenamide
|
|
CN114450028A
(zh)
|
2019-09-22 |
2022-05-06 |
百时美施贵宝公司 |
Lag-3拮抗剂治疗的定量空间剖析
|
|
EP4458975A3
(en)
|
2019-09-30 |
2025-02-12 |
Gilead Sciences, Inc. |
Hbv vaccines and methods treating hbv
|
|
JP6880352B1
(ja)
|
2019-11-07 |
2021-06-02 |
中外製薬株式会社 |
Ｋｒａｓ阻害作用を有する環状ペプチド化合物
|
|
EP4056580A4
(en)
|
2019-11-07 |
2023-12-06 |
Chugai Seiyaku Kabushiki Kaisha |
METHOD FOR PRODUCING A PEPTIDE COMPOUND COMPRISING A STERICALLY HINDERED AMINO ACID
|
|
EP4054723A1
(en)
|
2019-11-08 |
2022-09-14 |
Bristol-Myers Squibb Company |
Lag-3 antagonist therapy for melanoma
|
|
ES3022990T3
(en)
|
2019-12-06 |
2025-05-29 |
Prec Biosciences Inc |
Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome
|
|
JP2023510737A
(ja)
|
2020-01-06 |
2023-03-15 |
ブリストル－マイヤーズ スクイブ カンパニー |
免疫調節剤
|
|
CA3169348A1
(en)
|
2020-03-20 |
2021-09-23 |
Gilead Sciences, Inc. |
Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same
|
|
KR20220161407A
(ko)
|
2020-03-30 |
2022-12-06 |
브리스톨-마이어스 스큅 컴퍼니 |
면역조정제
|
|
WO2021205631A1
(ja)
|
2020-04-10 |
2021-10-14 |
小野薬品工業株式会社 |
Ｓｔｉｎｇ作動化合物
|
|
WO2021206158A1
(ja)
|
2020-04-10 |
2021-10-14 |
小野薬品工業株式会社 |
がん治療方法
|
|
CN113754736A
(zh)
*
|
2020-06-02 |
2021-12-07 |
南京礼威生物医药有限公司 |
含酰肼结构的pd-l1环肽抑制剂
|
|
CA3193421A1
(en)
|
2020-08-28 |
2022-03-03 |
Bristol-Myers Squibb Company |
Lag-3 antagonist therapy for hepatocellular carcinoma
|
|
CA3190660A1
(en)
|
2020-08-31 |
2022-03-03 |
George C. Lee |
Cell localization signature and immunotherapy
|
|
CA3193244A1
(en)
|
2020-09-22 |
2022-03-31 |
Geoffrey Martin Lynn |
Compositions and methods of manufacturing amphiphilic block copolymers that form nanoparticles in situ
|
|
US20240101666A1
(en)
|
2020-10-23 |
2024-03-28 |
Bristol-Myers Squibb Company |
Lag-3 antagonist therapy for lung cancer
|
|
WO2022120179A1
(en)
|
2020-12-03 |
2022-06-09 |
Bristol-Myers Squibb Company |
Multi-tumor gene signatures and uses thereof
|
|
WO2022212400A1
(en)
|
2021-03-29 |
2022-10-06 |
Juno Therapeutics, Inc. |
Methods for dosing and treatment with a combination of a checkpoint inhibitor therapy and a car t cell therapy
|
|
KR102666765B1
(ko)
*
|
2021-05-07 |
2024-05-16 |
추가이 세이야쿠 가부시키가이샤 |
환상 펩타이드 화합물의 의약 용도
|
|
AR125800A1
(es)
|
2021-05-07 |
2023-08-16 |
Chugai Pharmaceutical Co Ltd |
Métodos para producir compuestos cíclicos que comprendan residuos de aminoácidos sustituidos con n
|
|
AU2022274607A1
(en)
|
2021-05-13 |
2023-11-16 |
Gilead Sciences, Inc. |
COMBINATION OF A TLR8 MODULATING COMPOUND AND ANTI-HBV siRNA THERAPEUTICS
|
|
JP7673255B2
(ja)
|
2021-06-11 |
2025-05-08 |
ギリアード サイエンシーズ， インコーポレイテッド |
Ｍｃｌ－１阻害剤と抗体薬物コンジュゲートとの組み合わせ
|
|
TWI910028B
(zh)
|
2021-06-11 |
2025-12-21 |
美商基利科學股份有限公司 |
Mcl-1抑制劑與抗癌劑之組合
|
|
US11932634B2
(en)
|
2021-06-23 |
2024-03-19 |
Gilead Sciences, Inc. |
Diacylglycerol kinase modulating compounds
|
|
EP4359415A1
(en)
|
2021-06-23 |
2024-05-01 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
|
WO2022271650A1
(en)
|
2021-06-23 |
2022-12-29 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
|
WO2022271659A1
(en)
|
2021-06-23 |
2022-12-29 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
|
US20240417473A1
(en)
|
2021-10-29 |
2024-12-19 |
Bristol-Myers Squibb Company |
Lag-3 antagonist therapy for hematological cancer
|
|
IL314050A
(en)
|
2022-01-26 |
2024-09-01 |
Bristol Myers Squibb Co |
Combination therapy for hepatocellular carcinoma
|
|
IL315992A
(en)
|
2022-04-08 |
2024-11-01 |
Bristol Myers Squibb Co |
Identification, classification and quantification of tertiary lymphoid structures using machine learning
|
|
EP4578876A1
(en)
|
2022-08-23 |
2025-07-02 |
ONO Pharmaceutical Co., Ltd. |
Bispecific antibody
|
|
CN120731228A
(zh)
|
2022-12-21 |
2025-09-30 |
百时美施贵宝公司 |
肺癌的组合疗法
|
|
WO2024196952A1
(en)
|
2023-03-20 |
2024-09-26 |
Bristol-Myers Squibb Company |
Tumor subtype assessment for cancer therapy
|
|
WO2025193572A1
(en)
*
|
2024-03-11 |
2025-09-18 |
Bristol-Myers Squibb Company |
Macrocyclic peptides useful as immunomodulators
|
|
WO2025240244A1
(en)
|
2024-05-13 |
2025-11-20 |
Gilead Sciences, Inc. |
Combination therapies comprising bulevirtide and lonafarnib for use in the treatment of hepatitis d virus infection
|
|
WO2025240242A1
(en)
|
2024-05-13 |
2025-11-20 |
Gilead Sciences, Inc. |
Combination therapies with ribavirin
|
|
WO2025240243A1
(en)
|
2024-05-13 |
2025-11-20 |
Gilead Sciences, Inc. |
Combination therapies with bulevirtide and an inhibitory nucleic acid targeting hepatitis b virus
|
|
WO2025240246A1
(en)
|
2024-05-13 |
2025-11-20 |
Gilead Sciences, Inc. |
Combination therapies with ribavirin
|
|
WO2025245489A1
(en)
|
2024-05-24 |
2025-11-27 |
Bristol-Myers Squibb Company |
Treatment of tumors in subjects having fgl-1 positive samples
|